Astrana Health (NASDAQ:ASTH) reports Q3 2026 in line with expectations but quarterly revenue guidance misses expectations

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B, matching estimates, but missed EPS expectations at $0.71 vs $0.88. Q4 revenue guidance of $989M is below estimates. EBITDA beat slightly at $77.21M. Operating margin improved to 3.9% from 2% YoY.

Original reporting
Published Nov 5, 2026, 9:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astrana Health (NASDAQ:ASTH) reports Q3 2026 in line with expectations but quarterly revenue guidance misses expectations — source image
Decision brief

The 30-second read

$ASTHBearishMed
01

Why it matters

The earnings miss and weaker guidance are likely to pressure the stock in after‑hours trading, though margin expansion may soften the impact.

02

Market read

First‑time earnings disclosure with guidance miss; relevant for traders monitoring health‑tech equities.

03

What to watch

Strong operating margin improvement and stable free cash flow could support a longer‑term upside.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Astrana Health (NASDAQ:ASTH) posted Q3 2026 results with revenue matching estimates, but EPS fell short and guidance for Q4 revenue was below consensus.

Company-level read

Ticker impact

$ASTHBearishMedium confidence
Context

Astrana Health reported Q3 results in line with revenue expectations but missed EPS guidance and issued lower-than-expected Q4 revenue guidance.

Expected impact

likely downside as market prices in weaker guidance

Evidence & confidence

EPS miss and lower revenue outlook suggest weaker near‑term performance, prompting traders to consider short positions or reduce exposure.

Market effects

May weigh on other health‑tech firms with similar business models.

Limited to U.S. biotech/health‑tech segment.

Minimal global impact beyond sector peers.

Counterpoint

If the company can improve margins, the guidance miss may be temporary and present a buying opportunity.

Key entities

  • Astrana Health

    U.S. health‑technology firm reporting Q3 earnings.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.